This phase II trial studies how well vigamox works in treating patients with ocular graft-versus-host disease (GVHD). Vigamox is an antibiotic eye drop used to treat bacterial conjunctivitis. Giving vigamox may help treat the ocular involvement of GVHD.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04204122.
PRIMARY OBJECTIVE;
I. To prospectively measure the response of ocular GVHD patients to treatment with topical moxifloxacin hydrochloride (vigamox).
OUTLINE: Each patient's eyes are randomized to 1 of 2 groups.
GROUP I (EYES TREATED WITH MOXIFLOXACIN HYDROCHLORIDE): Patients use 1 drop of moxifloxacin hydrochloride to treat the eye 4 times daily (QID) for 7 days.
GROUP II (EYES TREATED WITH PLACEBO): Patients use 1 drop of placebo to treat the eye QID for 7 days.
After completion of study treatment, patients are followed up within 9-14 days.
Lead OrganizationSiteman Cancer Center at Washington University
Principal InvestigatorTodd P. Margolis
